What Research Tells Us About Treg Cells and Lyme Disease

The case for T-Regulatory cell therapy in chronic Lyme disease is not built on hypothesis alone. Over the past two decades, a growing body of peer-reviewed research has examined the role of regulatory T cells in Lyme disease progression, treatment response, and immune dysregulation — with findings that consistently point to the same conclusion: Treg function is not incidental to chronic Lyme disease. It is central to it.

This article reviews three significant studies retrieved from PubMed that illuminate what happens to immune regulation in Lyme disease — and why restoring it represents a fundamentally different, and more targeted, therapeutic strategy than antibiotic treatment alone.

Study 1: Treg numbers predict whether Lyme arthritis resolves

This study from Harvard Medical School and Massachusetts General Hospital examined Treg cell numbers and function in two groups of Lyme arthritis patients: those whose arthritis resolved with antibiotic treatment, and those for whom antibiotics failed — a condition termed antibiotic-refractory Lyme arthritis.

The findings were striking. In patients with antibiotic-refractory arthritis, FoxP3-positive Treg cells in synovial fluid were significantly higher than in peripheral blood — and a higher percentage of Tregs in the joint correlated directly with a shorter time to arthritis resolution. Patients with fewer Tregs had worse outcomes: they responded poorly to disease-modifying drugs and many required surgical synovectomies before their arthritis resolved.

The researchers also found that Treg cells in the synovial fluid were functionally capable of dampening Borrelia-specific immune responses — they were doing their job where they were present. The problem was not Treg dysfunction in this specific context, but Treg insufficiency: in patients who could not resolve their arthritis, the regulatory cell population was simply too depleted to do the work required.

Study 2: Depleting Tregs turns mild Lyme into severe arthritis

This study from the University of Wisconsin-Milwaukee took the question of Treg involvement one step further, using a controlled experimental model to directly test what happens when regulatory T cells are removed from Borrelia-infected subjects.

The researchers used a mouse strain that is normally resistant to Lyme arthritis — meaning infection causes minimal joint swelling. When Treg cells were depleted prior to Borrelia infection in these arthritis-resistant animals, the result was sustained joint swelling and histopathological joint damage that was not seen in infected mice with intact Treg populations.

The immune changes accompanying Treg depletion were equally significant. Splenocytes from Treg-depleted mice showed dramatically increased production of interferon-gamma (IFN-γ) and interleukin-17 — both pro-inflammatory cytokines — and decreased production of interleukin-10, the primary anti-inflammatory cytokine that Tregs normally produce. In other words, removing the regulatory brake transformed a restrained immune response into an overactivated one, even in animals biologically predisposed to resist the disease.

Critically, Treg depletion at various points after infection — not only before — also triggered rapid joint swelling. This suggests that Treg function is not only important for preventing initial inflammation, but for continuously maintaining the immune balance throughout the course of infection.

Study 3: Dysregulated cytokines drive post-infectious chronic Lyme

This comprehensive review in Nature Reviews Rheumatology synthesizes the current understanding of how Lyme disease transitions from infection to post-infectious chronic inflammatory disease. Published by researchers from Harvard Medical School, the Medical College of Wisconsin, the University of Utah, and the Wadsworth Center in Albany, it represents one of the most authoritative current summaries of the immunological mechanisms driving chronic Lyme.

The review identifies as its central finding that the defining feature of post-infectious Lyme arthritis is an excessive, dysregulated pro-inflammatory immune response during the infection phase that fails to resolve even after the spirochete has been killed. This response is characterized by abnormally high amounts of IFN-γ and inadequate amounts of the anti-inflammatory cytokine IL-10.

The consequences of this cytokine imbalance in joint tissue include impaired tissue repair, vascular damage, autoimmune processes, and progressive fibrosis. The review explicitly notes that these synovial characteristics are similar to those seen in rheumatoid arthritis — a condition driven by immune dysregulation, not ongoing infection.

This framing is significant for understanding why chronic Lyme is so difficult to treat with antibiotics alone: if the pathogen has been killed but the immune response continues to perpetuate inflammation, antimicrobial treatment addresses only the trigger — not the sustained mechanism. The mechanism — inadequate IL-10, excessive IFN-γ, absent regulatory control — requires a different kind of intervention.

What these studies collectively show

Taken together, the research retrieved from PubMed on this topic consistently supports several conclusions that are directly relevant to understanding why immune-focused treatment makes sense for chronic Lyme patients:

• Treg cell populations are measurably depleted or insufficient in patients with persistent Lyme inflammation
• Higher Treg numbers correlate with better and faster resolution of Lyme arthritis
• Experimentally removing Tregs converts mild, self-resolving Lyme into severe, sustained arthritis — proving causality, not merely correlation
• The characteristic cytokine pattern of chronic Lyme (high IFN-γ, low IL-10) reflects the direct consequence of failed Treg regulation
• Post-infectious chronic Lyme can persist and worsen even after the bacterium is eliminated, driven by immune dysregulation alone

These findings collectively support the premise that restoring functional regulatory T cell populations is not a peripheral consideration in chronic Lyme treatment — it is a direct response to the central biological mechanism driving the disease's persistence.

How this research informs our approach

At the Lyme Immunotherapy Center, the autologous Treg therapy program is built on the biological understanding that this research describes. The goal is not to stimulate the immune system — chronic Lyme patients' immune systems are already overactivated. The goal is to restore the regulatory architecture that allows the immune system to do what it is supposed to do: respond proportionally, reduce when appropriate, and stop producing the inflammatory signals that sustain damage long after the original trigger has been addressed.

The studies above provide the scientific foundation for this approach. They do not constitute proof that autologous Treg therapy will produce specific outcomes in any individual patient — each case is different, and no treatment guarantees resolution. But they establish clearly that Treg function is a legitimate and significant target in the treatment of chronic Lyme disease, and that addressing it represents a mechanistically sound strategy that conventional antibiotic treatment does not provide.